热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　建银国际发布研报称，华润医药（03320）2024年下半年销售额只同比增长5.9%，达到129.1亿元人民币，低过该行预期，下调对公司今明两年销售预测4.9%，降今明两年的每股盈利预测5.2%，至0.69元人民币及0.77元人民币，将目标价由6.4港元降至5.9港元，维持“跑赢大市”评级。

　　报告指，公司制造销售额同比增长7.5%，达到22.5亿元人民币，低于该行预期，原因是化学药品销售疲软，这受到API价格波动的影响。分销销售额同比增长6%，达到107.3亿元人民币，低于该行预期，因为医疗器械业务放缓。零售销售额同比增长2.1%，达到5.2亿元人民币，低于该行预期，因为强劲的DTP（直接面向患者）增长能够抵销实体零售业务的疲软。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.